ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Presentation will review the results of ONL’s Phase 1 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal Detachment Preclinical data in models of inherited retinal degeneration and age-related macular degeneration to be shared in poster presentations ANN ARBOR, MI – April 11, 2023 ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will deliver a podium presentation reviewing the results from a Phase 1 study to evaluate the safety of ONL1204 ophthalmic solution for the treatment of patients with macula-off rhegmatogenous retinal detachment (RRD) at the upcoming annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The ARVO Annual Meeting will take place April 23-27, 2023, at the Ernest N. Morial Convention Center in New Orleans, LA. ONL1204 Ophthalmic Solution is a first-in-class small molecule Fas inhibitor designed as a neuroprotectant for key retinal cells. ONL intends to initiate a Phase 2 clinical study of ONL1204 Ophthalmic Solution in patients suffering from macula-off RRD at sites in the U.S. in the second quarter of 2023. Details of the podium presentation are as follows: Title: Safety and Tolerability of Intravitreal ONL1204 in Patients with Macula-off Rhegmatogenous Retinal Detachment Presenter: Matthew Simunovic, MB BChir PhD FRANZCO Professor of Ophthalmology & Visual Science Faculty of Medicine and Health Clinical Ophthalmology and Eye Health Save Sight Institute Time/Date: 10:15 a.m. Central Daylight Time on Tuesday, April 25, 2023 Location: Room 353-355 The company will also present preclinical data on the protective effect of pharmacological Fas inhibition from models of inherited retinal degeneration and age-related macular degeneration in poster presentations. Details of the poster presentations are as follows: Session: #68 Age-related Macular Degeneration (AMD) New Drugs, Delivery Systems and Mechanisms of Action 2 Title: Fas Inhibition Preserves Retinal and Retinal Pigment Epithelium (RPE) Phenotype in a Chronic Smoke Exposure Model of AMD First Author: Marisol Cano, PhD, Research Associate, Wilmer Eye Institute – Johns Hopkins Medicine Time/Date: 3:45 p.m. – 5:30 p.m. Central Daylight Time on Sunday, April 23, 2023 Location: Exhibit hall – C0287 Session: #88 Inherited Retinal Degeneration Title: Protective Effect of Pharmacological Fas Inhibition in Two Mouse Models of Inherited Retinal Degeneration First Author: Jingyu Yao, PhD, Research Lab Specialist Senior, Department of Ophthalmology and Visual Sciences, University of Michigan Time/Date: 11:30 a.m. – 1:15 p.m. Central Daylight Time on Monday, April 24, 2023 Location: Exhibit hall – B0196 About ARVO The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include approximately 10,000 eye and vision researchers from over 75 countries. ARVO advances research worldwide into understanding the visual system and preventing, treating and curing its disorders. Learn more at ARVO.org . About ONL1204 Ophthalmic Solution ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions. Death of these retinal cells, through both direct and inflammatory signaling pathways, is the root cause of vision loss and the leading cause of blindness. The company’s later-stage clinical development program for ONL1204 currently includes a Phase 2 study in the U.S. for the treatment of macula-off retinal detachment ( NCT05730218 ), a condition for which the compound has been granted orphan drug designation by the United States Food and Drug Administration (FDA). The company is also conducting a Phase 1b clinical trial in patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD) ( NCT04744662 ) and a Phase 1b clinical trial in patients with progressing open-angle glaucoma ( NCT05160805 ), both being conducted at sites in Australia and New Zealand. Preclinical work is ongoing to enable clinical trials in other disease indications, including inherited retinal degeneration (IRD; also known as retinitis pigmentosa). About ONL Therapeutics ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision. ONL is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, AMD and IRD.For more information about ONL Therapeutics, please visit onltherapeutics.com . Company Contact ONL Therapeutics, Inc. Linda Kemnitz [email protected] Privacy Statement | Accessibility Statement | Terms of Use | Copyright All Rights Reserved ©2026 Manage Cookie Consent To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions. Functional Functional Always active Technical storage or access that is used strictly for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network. Preferences Preferences The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user. Statistics Statistics Technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. Marketing Marketing The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage options Manage services Manage {vendor_count} vendors Read more about these purposes Accept Deny View preferences Save preferences View preferences {title} {title} {title} Manage consent

The release as fetched from its publisher. onltherapeutics.com ↗